(SFZN) Siegfried Holding - SW
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: SW (Switzerland) | Market Cap: 2.918m CHF | Total Return: -27.3% in 12m
Avg Turnover: 6.31M
Warnings
Share dilution 906.0% YoY
Tailwinds
No distinct edge detected
Siegfried Holding AG is a Swiss-based Contract Development and Manufacturing Organization (CDMO) specializing in both drug substances and drug products. The company provides end-to-end services ranging from the exclusive synthesis of custom active pharmaceutical ingredients (APIs) to the final formulation and packaging of finished dosage forms.
The business model relies on high-barrier technical capabilities, including the production of sterile liquids, inhalation products, and viral vectors for gene therapy. CDMOs like Siegfried are integral to the pharmaceutical supply chain as drug developers increasingly outsource manufacturing to reduce capital expenditure and leverage specialized chemical expertise.
The company maintains a diverse API portfolio with a strategic focus on complex therapeutic areas such as anesthetics, pain management, and respiratory diseases. You can explore further valuation metrics and peer comparisons for this stock on ValueRay.
Headquartered in Zofingen and founded in 1873, Siegfried operates as a mid-cap player within the global healthcare sector, providing critical chemistry and formulation technologies to international pharmaceutical clients.
- API and drug product volume growth drives operating leverage
- High-margin sterile fill and finish capacity expansion boosts EBITDA
- Swiss franc appreciation creates significant currency translation headwinds
- Strategic acquisitions and facility integration accelerate CDMO market share gains
| Net Income: 168.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 1.09 > 1.0 |
| NWC/Revenue: 39.46% < 20% (prev 48.88%; Δ -9.42% < -1%) |
| CFO/TA 0.10 > 3% & CFO 221.9m > Net Income 168.7m |
| Net Debt (472.1m) to EBITDA (303.2m): 1.56 < 3 |
| Current Ratio: 2.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (43.8m) vs 12m ago 906.0% < -2% |
| Gross Margin: 26.66% > 18% (prev 25.42%; Δ 1.24% > 0.5%) |
| Asset Turnover: 64.97% > 50% (prev 66.95%; Δ -1.97% > 0%) |
| Interest Coverage Ratio: 23.86 > 6 (EBIT TTM 208.5m / Interest Expense TTM 8.74m) |
| A: 0.24 (Total Current Assets 1.05b - Total Current Liabilities 524.7m) / Total Assets 2.15b |
| B: 0.54 (Retained Earnings 1.17b / Total Assets 2.15b) |
| C: 0.10 (EBIT TTM 208.5m / Avg Total Assets 2.04b) |
| D: 1.10 (Book Value of Equity 1.13b / Total Liabilities 1.03b) |
| Altman-Z'' = 5.21 = AAA |
| DSRI: 1.20 (Receivables 504.3m/411.4m, Revenue 1.33b/1.29b) |
| GMI: 0.95 (GM 25.42% / 26.66%) |
| AQI: 0.94 (AQ_t 0.04 / AQ_t-1 0.04) |
| SGI: 1.03 (Revenue 1.33b / 1.29b) |
| TATA: -0.02 (NI 168.7m - CFO 221.9m) / TA 2.15b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of June 20, 2026, the stock is trading at CHF 67.95 with a total of 266,255 shares traded.
Over the past week, the price has changed by -7.55%,
over one month by -15.64%,
over three months by -8.32% and
over the past year by -27.34%.
Siegfried Holding has no consensus analysts rating.
P/E Trailing = 17.3438
P/E Forward = 16.2602
P/S = 2.1973
P/B = 2.6018
P/EG = 2.1426
Revenue TTM = 1.33b CHF
EBIT TTM = 208.5m CHF
EBITDA TTM = 303.2m CHF
Long Term Debt = 375.2m CHF (from longTermDebt, last quarter)
Short Term Debt = 200.0m CHF (from shortTermDebt, last quarter)
Debt = 575.2m CHF (from shortLongTermDebtTotal, last quarter)
Net Debt = 472.1m CHF (calculated: Debt 575.2m - CCE 103.1m)
Enterprise Value = 3.39b CHF (2.92b + Debt 575.2m - CCE 103.1m)
Interest Coverage Ratio = 23.86 (Ebit TTM 208.5m / Interest Expense TTM 8.74m)
EV/FCF = 339.9x (Enterprise Value 3.39b / FCF TTM 9.97m)
FCF Yield = 0.29% (FCF TTM 9.97m / Enterprise Value 3.39b)
FCF Margin = 0.75% (FCF TTM 9.97m / Revenue TTM 1.33b)
Net Margin = 12.70% (Net Income TTM 168.7m / Revenue TTM 1.33b)
Gross Margin = 26.66% ((Revenue TTM 1.33b - Cost of Revenue TTM 973.8m) / Revenue TTM)
Gross Margin QoQ = 26.97% (prev 26.31%)
Tobins Q-Ratio = 1.57 (Enterprise Value 3.39b / Total Assets 2.15b)
Interest Expense / Debt = 1.52% (Interest Expense 8.74m / Debt 575.2m)
Taxrate = 19.31% (40.3m / 208.7m)
NOPAT = 168.2m (EBIT 208.5m * (1 - 19.31%))
Current Ratio = 2.00 (Total Current Assets 1.05b / Total Current Liabilities 524.7m)
Debt / Equity = 0.51 (Debt 575.2m / totalStockholderEquity, last quarter 1.13b)
Debt / EBITDA = 1.56 (Net Debt 472.1m / EBITDA 303.2m)
Debt / FCF = 47.34 (Net Debt 472.1m / FCF TTM 9.97m)
Total Stockholder Equity = 999.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.25% (Net Income 168.7m / Total Assets 2.15b)
RoE = 16.87% (Net Income TTM 168.7m / Total Stockholder Equity 999.5m)
RoCE = 15.16% (EBIT 208.5m / Capital Employed (Equity 999.5m + L.T.Debt 375.2m))
RoIC = 9.54% (NOPAT 168.2m / Invested Capital 1.76b)
WACC = 6.81% (E(2.92b)/V(3.49b) * Re(7.91%) + D(575.2m)/V(3.49b) * Rd(1.52%) * (1-Tc(0.19)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 11.11 | Cagr: 0.50%
[DCF] Terminal Value 75.44% ; FCFF base≈9.97m ; Y1≈10.0m ; Y5≈10.6m
[DCF] Fair Price = N/A (negative equity: EV 165.0m - Net Debt 472.1m = -307.1m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 95.99 | Revenue CAGR: 2.10% | SUE: -0.06 | # QB: 0
EPS current Year (2026-12-31): EPS=3.95 | Chg30d=-0.64% | Revisions=+20% | GrowthEPS=+7.2% | GrowthRev=+4.6%
EPS next Year (2027-12-31): EPS=4.55 | Chg30d=-0.25% | Revisions=+20% | GrowthEPS=+15.0% | GrowthRev=+9.2%
[Analyst] Revisions Ratio: +20%